Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.45 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 3/20 | 0.41 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | CCNC | P24863 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Malic Acid SCHEMBL27610482 | 0.81 | SMN1; SMN2 (0.43) | BRD4BRD9PARP1PARP15PARP10 | |
| SCHEMBL6438124 | 0.80 | TPMT (0.44) | HSD17B10KDM4EALDH1A1SMN1; SMN2POLB | |
| SCHEMBL18315117 | 0.78 | PRSS1 (0.46) | LMNAPKMBLMHDAC3HDAC4 | |
| SCHEMBL20726642 | 0.78 | BRD4 (0.66) | BRD4BRD9PARP1PARP15PARP10 | |
| SCHEMBL34469515 | 0.77 | BRD4 (0.40) | BRD4BRD9PARP1PARP15PARP10 | |
| SCHEMBL24158944 | 0.75 | CYP2C9 (0.50) | BRD4BRD9PARP1PARP15PARP10 | |
| SCHEMBL18092436 | 0.75 | CA1 (0.45) | HSD17B10KDM4EALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL4848806 | 0.74 | ATM (0.57) | BRD4BRD9PARP1PARP15PARP10 | |
| SCHEMBL18584635 | 0.74 | BRD4 (0.49) | BRD4BRD9PARP1PARP15PARP10 | |
| SCHEMBL4848799 | 0.74 | BRD4 (0.38) | BRD4BRD9PARP1PARP15PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101939314-B | Polymorphic forms of a 3-pyrrole substituted 2-indolinone | MEDICHEM SA | 2014-04-02 | — | — | CN | claimed |
| CN-102740888-A | Antibodies to IL-6 and use there | ALDER BIOPHARMACEUTICALS INC | 2012-10-17 | — | — | CN | claimed |
| CN-101939314-A | Polymorphic forms of a 3-pyrrole substituted 2-indolinone | MEDICHEM SA | 2011-01-05 | — | — | CN | claimed |
| CN-100439360-C | Crystal of malate comprising N- [2- (diethylamino) ethyl ] -5- [ (5-fluoro-2-oxo-3H-indol-3-ylidene) methyl ] -2, 4-dimethyl-1H-pyrrole-3-carboxamide, method for preparing same and composition thereof | UPJOHN CO (US) | 2008-12-03 | — | — | CN | claimed |
| CN-100432072-C | Salts and polymorphs of a pyrrole-substituted indolinone compound | PHARMACIA & UPJOHN CO LLC (US) | 2008-11-12 | — | — | CN | claimed |
| CN-100364991-C | Crystals including a malic acid salt of a 3-pyrrole substituted 2-indolinone, and compositions thereof | UPJOHN CO (US) | 2008-01-30 | — | — | CN | claimed |
| CN-1863796-A | Salts and polymorphs of a pyrrole-substituted indolinone compound | PHARMACIA & UPJOHN CO LLC (US) | 2006-11-15 | — | — | CN | claimed |
| CN-1789264-A | Crystals including a malic acid salt of a 3-pyrrole substituted 2-indolinone, and compositions thereof | UPJOHN CO (US) | 2006-06-21 | — | — | CN | claimed |
| EP-1542734-A1 | ISOTOPICALLY LABELLED INDOLINONE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | Pharmacia Italia S.p.A. (IT) | 2005-06-22 | — | — | EP | claimed |
| CN-1543462-A | Crystal of malate comprising N- [ 2- (diethylamino) ethyl ] -5- [ (5-fluoro-2-oxo-3H-indol-3-ylidene) methyl ] -2, 4-dimethyl-1H-pyrrole-3-carboxamide, method for preparing same and composition thereof | �������Ŷ���Լ��������˾ | 2004-11-03 | — | — | CN | claimed |
| WO-2004012776-A1 | ISOTOPICALLY LABELLED INDOLINONE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | PHARMACIA ITALIA S.P.A. (IT) | 2004-02-12 | — | — | WO | claimed |
| US-12570645-B2 | Uses of p53 x-ray co-crystal structures | PMV PHARMACEUTICALS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260027097-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20250319063-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2025-10-16 | — | — | US | disclosed |
| US-12419880-B2 | Companion diagnostic tool for mutant p53 reactivating compounds | PMV PHARMACEUTICALS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| EP-1542734-A1 | ISOTOPICALLY LABELLED INDOLINONE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | Pharmacia Italia S.p.A. (IT) | 2005-06-22 | — | — | EP | disclosed |
| CN-1543462-A | Crystal of malate comprising N- [ 2- (diethylamino) ethyl ] -5- [ (5-fluoro-2-oxo-3H-indol-3-ylidene) methyl ] -2, 4-dimethyl-1H-pyrrole-3-carboxamide, method for preparing same and composition thereof | �������Ŷ���Լ��������˾ | 2004-11-03 | — | — | CN | disclosed |
| WO-2004012776-A1 | ISOTOPICALLY LABELLED INDOLINONE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | PHARMACIA ITALIA S.P.A. (IT) | 2004-02-12 | — | — | WO | disclosed |
| EP-1370554-A1 | 3-(4-AMIDOPYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002066463-A1 | 3-(4-AMIDOPYRROL-2-YLMETHLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319063-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | TP53, TP53BP1, KRAS | BRD4 1272/4885BRD9 3362/4885PARP1 865/4885 |
| US-20260027097-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, BRCA1 | BRD4 324/4885BRD9 185/4885PARP1 457/4885 |
| US-12570645-B2 | Uses of p53 x-ray co-crystal structures | TP53, TP53BP1, ERCC2 | BRD4 2324/4885BRD9 1744/4885PARP1 694/4885 |
| US-12419880-B2 | Companion diagnostic tool for mutant p53 reactivating compounds | TP53, TP53BP1, KRAS | BRD4 1089/4885BRD9 2090/4885PARP1 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.